1. Scrip

Merck's Keytruda Is First Checkpoint Inhibitor To Win US Approval Based On TMB Biomarker

 
• By Jessica Merrill

Merck has secured FDA approval for Keytruda for use in tumors with high tumor mutational burden, something Bristol's Opdivo and AstraZeneca's Imfinzi were not able to do in lung cancer.

Athlete in action of high jump.
Keytruda clears a bar for use in TMB-high tumors • Source: Shutterstock

Merck & Co. Inc.'s Keytruda (pembrolizumab) has secured a new tumor-agnostic indication from the US Food and Drug Administration for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors. Other PD-1/L1 inhibitors, including Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and AstraZeneca PLC's Imfinzi (durvalumab) have both pursued high TMB in lung cancer without success.

The 16 June FDA approval was an accelerated approval based on retrospective analysis of data from 10 cohorts of patients with previously treated unresectable or metastatic solid tumors with TMB-H...

More from New Products

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.